All posts by admin

USA Far Ocean Group Inc. Issues Voluntary Nationwide Recall of Vagifresh Ball and Vagifresh Gel, Marketed Individually or Under a Mixed Package Named Female One

USA Far Ocean Group Inc. (U.S.A. Far Ocean), is voluntarily recalling the Company’s two products sold as cosmetic under the names Vagifresh Ball and Vagifresh Gel. These two products were also sold under the mixed package named Female One, which contained Vagifresh Ball, Vagifresh Gel and Vagifresh Liquid (this recall does not involve Vagifresh Liquid).

Winn-Dixie Issues Voluntary Recall On LEASA Brand Sprouts Due To Potential Salmonella Exposure

Winn-Dixie Stores, Inc., today announced an immediate Class I voluntary recall of all LEASA Living Alfalfa Sprouts sold in the 6 oz. package with a UPC code of 7546555912. According to the Federal Drug Administration (FDA), the product is potentially contaminated with Salmonella, an organism that can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems.

Leasa Industries Co., Inc. Recalls Leasa Brand 6 oz. Living Alfalfa Sprouts Because Of Possible Health Risk

Leasa Industries Co., Inc. of Miami, FL is recalling 346 cases of LEASA Living Alfalfa Sprouts with use by date 2/1/12, because it has the potential to be contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems. Healthy persons infected with Salmonella often experience fever, diarrhea (which may be bloody), nausea, vomiting and abdominal pain.
Read The Complete Story!

FDA approves Voraxaze to treat patients with toxic methotrexate levels

The U.S. Food and Drug Administration today approved Voraxaze (glucarpidase) to treat patients with toxic levels of methotrexate in their blood due to kidney failure.

Methotrexate is a commonly used cancer chemotherapy drug normally eliminated from the body by the kidneys. However, patients receiving high doses of methotrexate may develop kidney failure.

FDA completes work on three drug user fee programs

The U.S. Food and Drug Administration has completed its recommendations for three user fee programs that will help speed safe and effective drugs and lower-cost generic drug and biosimilar biological products to patients, FDA Commissioner Margaret A. Hamburg, M.D. said today. The recommendations were transmitted to Congress today by Health and Human Services Secretary Kathleen Sebelius.